V. Parra-izquierdo, J. Frías-Ordoñez, Consuelo Romero-Sanchez, F. Puentes-Manosalva, Diana Mora, John Garces, C. Cuadros, Fernando Sarmiento, Melquisedec Vargas, Carolina Samper, Mariastella Serrano
{"title":"S85 Evaluation of Quality of Life in Health by IMPACT-III in Colombian Pediatric Patients With Inflammatory Bowel Disease","authors":"V. Parra-izquierdo, J. Frías-Ordoñez, Consuelo Romero-Sanchez, F. Puentes-Manosalva, Diana Mora, John Garces, C. Cuadros, Fernando Sarmiento, Melquisedec Vargas, Carolina Samper, Mariastella Serrano","doi":"10.14309/01.ajg.0000996084.75247.15","DOIUrl":null,"url":null,"abstract":"Background: Among patients with ulcerative colitis (UC), prior exposure to biologics or advanced therapies is associated with reduced response to future therapies, which may lead to treatment discontinuation. Therapy persistence is a proxy of real-world treatment performance and is important to achieve optimal clinical outcomes. This study compared persistence among advanced therapy-experienced patients with UC initiated on ustekinumab, an anti-interleukin 12/23 antibody, or adalimumab","PeriodicalId":188050,"journal":{"name":"The American Journal of Gastroenterology","volume":"89 1","pages":"S23 - S23"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14309/01.ajg.0000996084.75247.15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Among patients with ulcerative colitis (UC), prior exposure to biologics or advanced therapies is associated with reduced response to future therapies, which may lead to treatment discontinuation. Therapy persistence is a proxy of real-world treatment performance and is important to achieve optimal clinical outcomes. This study compared persistence among advanced therapy-experienced patients with UC initiated on ustekinumab, an anti-interleukin 12/23 antibody, or adalimumab
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
